他汀类药物与癌症风险：随机、双盲、安慰剂对照试验的荟萃分析

Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials.

作者信息

Kim M K, Myung S K, Tran B T, Park B

机构信息

Department of Cancer Control and Population Health; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.

Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy; Cancer Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute; Department of Family Medicine and Center for Cancer Prevention and Detection, National Cancer Center, Goyang, Republic of Korea.

出版信息

Indian J Cancer. 2017 Apr-Jun;54(2):470-477. doi: 10.4103/ijc.IJC_214_17.

DOI:10.4103/ijc.IJC_214_17

PMID:29469081

Abstract

PURPOSE

Several meta-analyses of randomized controlled trials (RCTs) reported no association between the use of statins and the risk of cancer. However, they included open-label RCTs, which did not use placebo as a control group. This study aimed to evaluate the effect of statins on cancer risk using a meta-analysis of randomized, double-blind, placebo-controlled trials (RDBPCTs).

METHODS

We searched PubMed, EMBASE, and the Cochrane Library in March 2016. Two individual authors reviewed and selected RDBPCTs based on selection criteria.

RESULTS

Out of 676 retrieved articles, a total of 21 RDBPCTs with 65,196 participants (32,618 in the statin group and 32,578 in the placebo group) were included in the meta-analysis. Overall, we found that there was no significant association between the use of statins and the risk of cancer (relative risk 0.97, 95% confidence interval 0.92-1.02, I = 0.0%) in a fixed-effect meta-analysis. In addition, in the subgroup meta-analyses, no beneficial effect of statins was observed when analyzed by statin type, country, follow-up period, methodological quality, underlying diseases/population, and type of cancer.

CONCLUSIONS

The current meta-analysis of RDBPCTs found that there was no association between the use of statins and the risk of cancer.

摘要

目的

多项随机对照试验（RCT）的荟萃分析报告称，他汀类药物的使用与癌症风险之间没有关联。然而，这些分析纳入了开放标签的RCT，其未将安慰剂作为对照组。本研究旨在通过对随机、双盲、安慰剂对照试验（RDBPCT）进行荟萃分析，评估他汀类药物对癌症风险的影响。

方法

我们于2016年3月检索了PubMed、EMBASE和Cochrane图书馆。两位独立作者根据选择标准对RDBPCT进行了审查和筛选。

结果

在检索到的676篇文章中，共有21项RDBPCT纳入荟萃分析，涉及65196名参与者（他汀类药物组32618名，安慰剂组32578名）。总体而言，我们发现在固定效应荟萃分析中，他汀类药物的使用与癌症风险之间没有显著关联（相对风险0.97，95%置信区间0.92 - 1.02，I² = 0.0%）。此外，在亚组荟萃分析中，按他汀类药物类型、国家、随访期、方法学质量、基础疾病/人群和癌症类型分析时，未观察到他汀类药物有有益作用。